Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca study highlights long-term safety of Vimovo

AstraZeneca study highlights long-term safety of Vimovo

28th March 2011

AstraZeneca has published a new study that highlights the long-term safety performance of Vimovo among certain at-risk osteoarthritis patients.

The drug was trialled over 12 months among subjects who were susceptible to gastric ulcers as a result of treatment with non-steroidal anti-inflammatory drugs (NSAIDs) such as Vimovo.

It was found that AstraZeneca's product was generally well-tolerated among users, with no new or unexpected safety issues highlighted by the phase III trial.

Dr Mark Sostek, executive director for clinical research at AstraZeneca, said this demonstrates the suitability of the drug among a patient population that requires NSAID therapy to relieve the pain of osteoarthritis.

He added: "In a single tablet, Vimovo delivers both the proven pain relief of naproxen with the gastric ulcer risk reduction of esomeprazole in every dose of the medication."

Last week, AstraZeneca announced that it is allying with Senectus Therapeutics to conduct new studies into cancer cell ageing processes.ADNFCR-8000103-ID-800477571-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.